Ceramide levels in blood plasma correlate with major depressive disorder severity and its neutralization abrogates depressive behavior in mice.


Journal

The Journal of biological chemistry
ISSN: 1083-351X
Titre abrégé: J Biol Chem
Pays: United States
ID NLM: 2985121R

Informations de publication

Date de publication:
08 2022
Historique:
received: 04 03 2022
revised: 11 05 2022
accepted: 21 06 2022
pubmed: 27 6 2022
medline: 9 9 2022
entrez: 26 6 2022
Statut: ppublish

Résumé

Major depressive disorder (MDD) is a severe disease of unknown pathogenesis that will affect ∼10% of people during their lifetime. Therapy for MDD requires prolonged treatment and often fails, predicating a need for novel treatment strategies. Here, we report increased ceramide levels in the blood plasma of MDD patients and in murine stress-induced models of MDD. These blood plasma ceramide levels correlated with the severity of MDD in human patients and were independent of age, sex, or body mass index. In addition, intravenous injection of anti-ceramide antibodies or neutral ceramidase rapidly abrogated stress-induced MDD, and intravenous injection of blood plasma from mice with MDD induced depression-like behavior in untreated mice, which was abrogated by ex vivo preincubation of the plasma with anti-ceramide antibodies or ceramidase. Mechanistically, we demonstrate that ceramide accumulated in endothelial cells of the hippocampus of stressed mice, evidenced by the quantitative measurement of ceramide in purified hippocampus endothelial cells. We found ceramide inhibited the activity of phospholipase D (PLD) in endothelial cells in vitro and in the hippocampus in vivo and thereby decreased phosphatidic acid in the hippocampus. Finally, we show intravenous injection of PLD or phosphatidic acid abrogated MDD, indicating the significance of this pathway in MDD pathogenesis. Our data indicate that ceramide controls PLD activity and phosphatidic acid formation in hippocampal endothelial cells and thereby mediates MDD. We propose that neutralization of plasma ceramide could represent a rapid-acting targeted treatment for MDD.

Identifiants

pubmed: 35753355
pii: S0021-9258(22)00627-5
doi: 10.1016/j.jbc.2022.102185
pmc: PMC9304786
pii:
doi:

Substances chimiques

Ceramides 0
Phosphatidic Acids 0
Phospholipase D EC 3.1.4.4

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

102185

Informations de copyright

Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Conflict of interests The authors declare that they have no conflicts of interest with the contents of this article.

Auteurs

Fabian Schumacher (F)

Department of Molecular Biology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany; Freie Universität Berlin, Institute of Pharmacy, Berlin, Germany.

Michael J Edwards (MJ)

Department of Molecular Biology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.

Christiane Mühle (C)

Department of Psychiatry and Psychotherapy, University Clinic, Friedrich-Alexander-University of Erlangen-Nuremberg, Erlangen, Germany.

Alexander Carpinteiro (A)

Department of Molecular Biology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.

Greg C Wilson (GC)

Department of Surgery, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.

Barbara Wilker (B)

Department of Molecular Biology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.

Matthias Soddemann (M)

Department of Molecular Biology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.

Simone Keitsch (S)

Department of Molecular Biology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.

Norbert Scherbaum (N)

Faculty of Medicine, Department of Psychiatry and Psychotherapy, LVR-Hospital Essen, University of Duisburg-Essen, Essen, Germany.

Bernhard W Müller (BW)

Faculty of Medicine, Department of Psychiatry and Psychotherapy, LVR-Hospital Essen, University of Duisburg-Essen, Essen, Germany; Department of Psychology, University of Wuppertal, Wuppertal, Germany.

Undine E Lang (UE)

Department für Psychiatry and Psychotherapy, University Psychiatric Clinics (UPK), University of Basel, Basel, Switzerland.

Christoph Linnemann (C)

Department für Psychiatry and Psychotherapy, University Psychiatric Clinics (UPK), University of Basel, Basel, Switzerland.

Burkhard Kleuser (B)

Freie Universität Berlin, Institute of Pharmacy, Berlin, Germany.

Christian P Müller (CP)

Department of Psychiatry and Psychotherapy, University Clinic, Friedrich-Alexander-University of Erlangen-Nuremberg, Erlangen, Germany; Centre for Drug Research, Universiti Sains Malaysia, Minden, Penang, Malaysia.

Johannes Kornhuber (J)

Department of Psychiatry and Psychotherapy, University Clinic, Friedrich-Alexander-University of Erlangen-Nuremberg, Erlangen, Germany.

Erich Gulbins (E)

Department of Molecular Biology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany. Electronic address: erich.gulbins@uni-due.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH